Orchestra BioMed Holdings, Inc. (OBIO)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue TTM

0 15M 30M 45M Q4 '22: 3.5M Q1 '23: 3.8M Q2 '23: 4.3M Q3 '23: 3.6M Q4 '23: 2.8M Q1 '24: 2.2M Q2 '24: 2.1M Q3 '24: 2.6M Q4 '24: 2.6M Q1 '25: 2.9M Q2 '25: 2.9M Q3 '25: 2.8M Q4 '25: 33.5M Q1 '26: 32.7M Q2 '26: 32M Q4 '22 Q2 '23 Q4 '23 Q2 '24 Q4 '24 Q2 '25 Q4 '25 Q2 '26

Gross Profit TTM

0 15M 30M 45M Q4 '22: 3.3M Q1 '23: 3.6M Q2 '23: 4.1M Q3 '23: 3.4M Q4 '23: 2.6M Q1 '24: 2M Q2 '24: 1.9M Q3 '24: 2.5M Q4 '24: 2.4M Q1 '25: 2.7M Q2 '25: 2.7M Q3 '25: 2.6M Q4 '25: 33.3M Q1 '26: 32.5M Q2 '26: 31.8M Q4 '22 Q2 '23 Q4 '23 Q2 '24 Q4 '24 Q2 '25 Q4 '25 Q2 '26

Revenue minus cost of sales. This filer tags no gross profit of its own..

Operating Income TTM

-90M -60M -30M 0 30M 60M 90M Q3 '21: -398.9K Q4 '21: -394.8K Q1 '22: -5.4M Q2 '22: -12.9M Q3 '22: -22.9M Q4 '22: -32.7M Q1 '23: -39.1M Q2 '23: -44.4M Q3 '23: -48.9M Q4 '23: -51.5M Q1 '24: -54.4M Q2 '24: -58.3M Q3 '24: -60.1M Q4 '24: -64.3M Q1 '25: -68.8M Q2 '25: -71.3M Q3 '25: -75.2M Q4 '25: -51.8M Q1 '26: -55M Q2 '26: -58M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Net Income TTM

-90M -60M -30M 0 30M 60M 90M Q3 '21: -382.9K Q4 '21: -378.8K Q1 '22: -6M Q2 '22: -13.8M Q3 '22: -23.9M Q4 '22: -33.6M Q1 '23: -38.8M Q2 '23: -43M Q3 '23: -46.1M Q4 '23: -49.1M Q1 '24: -51.6M Q2 '24: -55.6M Q3 '24: -57.7M Q4 '24: -61M Q1 '25: -66.3M Q2 '25: -69.7M Q3 '25: -75.1M Q4 '25: -52.7M Q1 '26: -54.6M Q2 '26: -59M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Cost of Revenue TTM

0 80K 160K 240K Q4 '22: 211K Q1 '23: 213K Q2 '23: 207K Q3 '23: 192K Q4 '23: 186K Q1 '24: 176K Q2 '24: 166K Q3 '24: 193K Q4 '24: 204K Q1 '25: 214K Q2 '25: 216K Q3 '25: 197K Q4 '25: 190K Q1 '26: 178K Q2 '26: 157K Q4 '22 Q2 '23 Q4 '23 Q2 '24 Q4 '24 Q2 '25 Q4 '25 Q2 '26

Operating Cash Flow TTM

-75M -50M -25M 0 25M 50M 75M Q3 '21: -254.5K Q4 '21: -272.4K Q1 '22: -5.5M Q2 '22: -13.4M Q3 '22: -20.6M Q4 '22: -29.3M Q1 '23: -38.3M Q2 '23: -40.9M Q3 '23: -43.9M Q4 '23: -46.1M Q1 '24: -44.9M Q2 '24: -44.6M Q3 '24: -48M Q4 '24: -50.6M Q1 '25: -54.1M Q2 '25: -59.4M Q3 '25: -60.2M Q4 '25: -49M Q1 '26: -54.5M Q2 '26: -58.3M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Free Cash Flow TTM

-75M -50M -25M 0 25M 50M 75M Q4 '22: -29.9M Q1 '23: -38.9M Q2 '23: -41.2M Q3 '23: -44M Q4 '23: -46.2M Q1 '24: -44.9M Q2 '24: -44.7M Q3 '24: -48.2M Q4 '24: -50.8M Q1 '25: -54.5M Q2 '25: -59.7M Q3 '25: -60.8M Q4 '25: -49.5M Q1 '26: -55.1M Q2 '26: -59.1M Q4 '22 Q2 '23 Q4 '23 Q2 '24 Q4 '24 Q2 '25 Q4 '25 Q2 '26

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 25M 50M 75M Q1 '21: 20.4M Q2 '21: 20.4M Q3 '21: 20.4M Q1 '22: 9.2M Q2 '22: 10.1M Q3 '22: 20.2M Q1 '23: 27.6M Q2 '23: 34.6M Q3 '23: 35.2M Q1 '24: 35.8M Q2 '24: 35.8M Q3 '24: 37.6M Q1 '25: 38.2M Q2 '25: 38.4M Q3 '25: 52.2M Q1 '26: 62.7M Q2 '26: 63.8M Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-2.40 -1.60 -0.80 0.00 0.80 1.60 2.40 Q3 '21: 0.00 Q4 '21: -0.01 Q1 '22: -0.63 Q2 '22: -1.40 Q3 '22: -1.91 Q4 '22: -2.34 Q1 '23: -2.12 Q2 '23: -1.70 Q3 '23: -1.57 Q4 '23: -1.50 Q1 '24: -1.48 Q2 '24: -1.58 Q3 '24: -1.61 Q4 '24: -1.67 Q1 '25: -1.78 Q2 '25: -1.83 Q3 '25: -1.82 Q4 '25: -1.11 Q1 '26: -0.95 Q2 '26: -0.83 Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.